Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02341625 · ClinicalTrials.gov registry record · Phase 1
A Study of BMS-986148 in Patients With Select Advanced Solid Tumors
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Terminated
- Registry status
- Phase 1
- Development phase
- 126
- Enrollment target
NCT02341625 is a Phase 1 study that was terminated before completion, run by Bristol-Myers Squibb. The registered enrollment target is 126 participants.
The verdict
NCT02341625, a Phase 1 study, was terminated before completion, sponsored by Bristol-Myers Squibb.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 126 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety, tolerability, pharmacokinetics, immunogenicity, antitumor activity and pharmacodynamics of BMS-986148 administered alone and in combination with nivolumab in patients with mesothelioma, non-small cell lung cancer, ovarian cancer, pancreatic cancer and gastric cancer.
Interventions
- BIOLOGICAL Nivolumab
- DRUG BMS-986148
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 126 participants |
| Start Date | 2015-06-19 |
| Est. Completion | 2020-05-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02341625
The ClinicalTrials.gov registry entry for NCT02341625 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 126 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nivolumab is the first listed.
NCT02341625 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02341625 about?
NCT02341625 is a clinical study titled "A Study of BMS-986148 in Patients With Select Advanced Solid Tumors". The purpose of this study is to determine the safety, tolerability, pharmacokinetics, immunogenicity, antitumor activity and pharmacodynamics of BMS-986148 administered alone and in combination with nivolumab in patients with mesothelioma, non-small cell lung cancer, ovarian cancer, pancreatic cance...
What is the current status of trial NCT02341625?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 126 participants. The study started on 2015-06-19. Estimated completion is 2020-05-07.
What interventions are being tested in trial NCT02341625?
The interventions under investigation include: Nivolumab (BIOLOGICAL), BMS-986148 (DRUG).
Who is sponsoring clinical trial NCT02341625?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.